Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
Grouped treatment entry. The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
3 studies reference this grouped treatment entry.
3 studies mention this registry entry. Counts describe the source entry and do not establish exposure to an individual molecule.
Registry-listed formulations
This catalogue entry has no confirmed scientific concept.
Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.
0 source entries across 0 studies. This list may not include all unresolved or historical entries.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
2
trials recruiting
3
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia
Clinical Trials (3)
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia
All 3 trials loaded
Drug Details
- Intervention Type
- Drug
- Total Trials
- 3